Imtiaz Salman, Dhrolia Murtaza Fakhruddin, Nasir Kiran, Salman Beena, Ahmad Aasim
The Kidney Centre Postgraduate Training Institute, Karachi.
J Pak Med Assoc. 2015 Sep;65(9):995-1000.
To see the response of steroid and cyclophosphamide if membranoproliferative glomerulonephritis is classified by pattern of immune and complement deposits.
The retrospective study was conducted at The Kidney Centre, Karachi, and comprised patients treated for membranoproliferative glomerulonephritis between 1996 and 2013. Records of patients who were not treated with immunosuppressive medications were excluded. Patients were classified according to the types of immune deposits; one group had patients with only Complement factor 3 deposits, and the other with Complement factor 3 and immunoglobulin deposits. The effect of steroid alone and steroid with cyclophosphamide was observed on two histological patterns, according to the severity of kidney dysfunction and degree of interstitial fibrosis. SPSS 17 was used for statistical analysis.
Of the 54 patients, 31(57%) were males and 23(42%) were females, with an overall mean age of 30.26±15.41 years. Group with Complement factor 3deposits had 17(31%) patients, while that with Complement factor 3 and immunoglobulin had 37(68%). Both groups were similar in terms of clinical and laboratory parameters (p>0.05). Both groups showed better response when treated with steroid and cyclophosphamide: 8/9(88.9%) vs. 3/8(37.5%) in Complement factor 3 only; and 10/15(66.7%) vs. 12/22(54.5%) in Complement factor 3 with immunoglobulin. Increasing severity of interstitial fibrosis (p=0.014) and presence of renal dysfunction (p=0.001) hampered the response. After adjusting the confounders, the odds ratio of response was 4.654(95%confidence interval: 0.957-22.63) in patients who received the treatment with steroid and cyclophosphamide compared to steroid alone.
Steroids and cyclophosphamide together have a beneficial role if treatment is initiated early in the course of the disease.
根据免疫和补体沉积模式对膜增生性肾小球肾炎进行分类,观察类固醇和环磷酰胺的疗效。
本回顾性研究在卡拉奇肾脏中心进行,纳入1996年至2013年间接受膜增生性肾小球肾炎治疗的患者。排除未接受免疫抑制药物治疗的患者记录。根据免疫沉积物类型对患者进行分类;一组患者仅有补体因子3沉积,另一组有补体因子3和免疫球蛋白沉积。根据肾功能不全的严重程度和间质纤维化程度,观察单独使用类固醇以及类固醇联合环磷酰胺对两种组织学模式的影响。采用SPSS 17进行统计分析。
54例患者中,男性31例(57%),女性23例(42%),总体平均年龄为30.26±15.41岁。仅有补体因子3沉积的组有17例(31%)患者,有补体因子3和免疫球蛋白沉积的组有37例(68%)。两组在临床和实验室参数方面相似(p>0.05)。两组在接受类固醇和环磷酰胺治疗时均显示出更好的反应:仅补体因子3沉积组为8/9(88.9%)对3/8(37.5%);补体因子3和免疫球蛋白沉积组为10/15(66.7%)对12/22(54.5%)。间质纤维化严重程度增加(p=0.014)和存在肾功能不全(p=0.001)会阻碍反应。在调整混杂因素后,与单独使用类固醇相比,接受类固醇和环磷酰胺治疗的患者反应的优势比为4.654(95%置信区间:0.957 - 22.63)。
如果在疾病早期开始治疗,类固醇和环磷酰胺联合使用具有有益作用。